Literature DB >> 6104653

Inhibition of neutral proteases from polymorphonuclear (PMN) neutrophils by salicylazosulfapyridine (SASP).

C Klessen.   

Abstract

Cytochemical methods were used to demonstrate the inhibitory effect of salicylazosulfapyridine (SASP) on the activity of neutral proteases produced by neutrophilic granulocytes (PMN proteases). The SASP metabolites (5-aminosalicylic acid and sulfapyridine), produced by splitting of SASP by bacteria in the colon, did not inhibit the activity of PMN proteases. Paradoxically, sulfapyridine intensified PMN protease activity. A similar effect however could not be demonstrated for 5-aminosalicylic acid.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104653     DOI: 10.1007/bf00493244

Source DB:  PubMed          Journal:  Histochemistry        ISSN: 0301-5564


  7 in total

1.  Distribution and metabolism of salicyl-azo-sulfapyridine. I. A study with C-14-5-amino-salicylic acid.

Authors:  A HANNGREN; E HANSSON; N SVARTZ; S ULLBERG
Journal:  Acta Med Scand       Date:  1963-01

2.  [Simplification of the reaction after Hale (1946)].

Authors:  G MULLER
Journal:  Acta Histochem       Date:  1955-09-26       Impact factor: 2.479

3.  On testing the activity of proteases from human polymorphonuclear neutrophils on blood smears.

Authors:  C Klessen
Journal:  J Histochem Cytochem       Date:  1978-09       Impact factor: 2.479

4.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

5.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

6.  Treatment of ulcerative colitis with salazopyrin.

Authors:  N Svartz
Journal:  Int Surg       Date:  1968-11

7.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.